More Than Medicine
Welcome to Novo Nordisk’s Scientific Exchange. Designed to foster the exchange of scientific information, the site provides access to educational information about Novo Nordisk’s medicines, therapeutic areas of interest, and congress activities. All content is intended for use by U.S. Healthcare Professionals only.
Explore content by therapeutic area
Explore content by therapeutic area
Featured in
Congress materials
View posters, abstracts and other disease-related materials presented at recent congresses.
American Diabetes Association (ADA) Materials
View posters and presentations from the ADA 2024 conference on the Novo Nordisk Science Hub.
American Neurological Association (ANA) Materials
Featured in
Disease education
Review information important to the clinical understanding of patient care.
Obesity: an overview of the disease - English version
ADA Standards of Medical Care in Diabetes – 2024
Algorithms and updates from the 2024 guidelines.
SELECT: cardiovascular outcome trial in obesity
The SELECT trial evaluated the effect of semaglutide 2.4 mg once weekly on cardiovascular outcomes in patients with overweight or obesity and cardiovascular disease.
Find product information
Survey Novo Nordisk’s portfolio of products and resources for the treatment of diabetes, obesity, liver health, and cardiovascular disease and treatments for rare bleeding, rare endocrine, and rare renal disorders.
Continuing education
Learn about accredited CE activities developed by third-party providers and supported by Novo Nordisk via independent medical education grants.
Find more information
Speak to a medical representative
If you are a healthcare provider from the United States, click below to request information directly from the Novo Nordisk Medical Information department. If you are a patient, please visit here to contact us, or call 1-800-727-6500.
Search the Medical Information Database
The Scientific Exchange is a resource for U.S. Healthcare Professionals to learn more about disease states investigated by Novo Nordisk and our related products.
The purpose of this site is to provide relevant medical and scientific information about Novo Nordisk products and areas of therapeutic interest. Information about investigational products or investigational uses of approved products neither implies FDA approval for these products or uses, nor establishes the safety or efficacy of these products or uses. There is no guarantee that any investigational product or investigational use will receive FDA approval or become commercially available in the United States. Novo Nordisk does not recommend or suggest use of its products in any manner inconsistent with FDA-approved labeling.
This site is intended for United States healthcare professionals only. The information on this site—including all product information—pertains to residents of the United States only. Any products referenced on this site may have different labelling in different countries.
